• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

Home > Press releases

Network of experts calls for urgent boost to research and development of rapid tests for cutaneous leishmaniasis in Latin America

Laboratory assistant conducts analysis at laboratory in Peru
CARTAGENA DE INDIAS — 3 Aug 2022
  • English
    • English
    • Español
    • Português

redeLEISH, the leishmaniasis research network, released a manifesto during the WorldLeish 7 international conference calling on the scientific community and health authorities to prioritize the need to develop simple diagnostic tools for cutaneous leishmaniasis (CL).

According to the World Health Organization (WHO), approximately one million people worldwide are affected by CL. People affected by the disease develop single or multiple lesions on different parts of the body, which leads to social stigma, psychological distress, and economic losses. Despite its broad geographic distribution and its devastating impact on vulnerable communities, research and development (R&D) for this type of leishmaniasis still attracts very little investment.

The lack of availability of adequate tools for the diagnosis of CL is one of the biggest challenges to reaching the target of eliminating this disease as a public health problem, as set in WHO’s Road Map for Neglected Tropical Diseases, 2021-2030.

‘The lack of rapid diagnostic tests that are highly effective, accessible and easy to use in primary care makes it difficult to detect and treat CL early, compounding the suffering of the people impacted by the disease,’ said Joelle Rode, Senior Leishmaniasis Clinical Project Manager at the Drugs for Neglected Diseases initiative (DNDi).

Experts signing the redeLEISH Manifesto at WorldLeish 7

In an effort to guide the development of rapid diagnostic tools, the Foundation for Innovative New Diagnostics (FIND) set forth with experts a target product profile (TPP) with the requirements for an ideal CL test. ‘The development of a rapid test guided by criteria consensually defined and agreed upon, and which may be implemented in low-resource environments, must be a priority for the scientific community, governments and donors,’ said Israel Cruz, Head of International Health at the National School of Public Health, Instituto de Salud Carlos III, and a FIND collaborator.

The TPP was recently reviewed and supported by the WHO Diagnostic Technical Advisory Group (DTAG) for Neglected Tropical Disease Diagnostics.

Released today during the 7th edition of WorldLeish, the world’s foremost scientific conference on leishmaniasis, the manifesto highlights the challenging environment in endemic countries and the urgent need for more incentives for R&D of diagnostic tests for CL. According to a report from G-FINDER, a mere USD 100,000 was invested in 2020 for R&D of diagnostic tools for leishmaniasis, representing less than 0.5% of global R&D investment for the disease (USD 45 million in total).

‘Through this manifesto, we researchers pledge to contribute to the creation of a common strategic agenda aiming at the production, validation, implementation and access to adequate new diagnostics tools for CL,’ said Glaucia Cota, Coordinator of the Leishmaniasis Reference Group at the Instituto René Rachou, from Brazil’s Fundação Oswaldo Cruz (FIOCRUZ).

Read the manifesto

About redeLEISH

redeLEISH brings together around 200 experts from 91 organizations around the world who are engaged in strengthening collaborations and maximizing R&D efforts for cutaneous leishmaniasis. Created in 2014, the initiative supports the implementation of clinical trials for the evaluation of new therapeutic tools for the leishmaniases, promotes the harmonization of criteria for the conduction of clinical trials, and facilitates the information sharing on treatments, diagnostics and research developments in CL. With representatives in 28 countries, the network operates through a virtual forum to assist in technical-scientific exchanges, publishing annual newsletters, and through in-person meetings that allow the identification of research priorities and the articulation of collaborative projects.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in low- and middle-income countries. Since its inception in 2003, DNDi has delivered twelve new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Media contact

DNDi
Marcela Dobarro
mdobarro@dndi.org
+55 21 981149429

Photo credit: Vinicius Berger – DNDi

Policy advocacy Cutaneous leishmaniasis

Read, watch, share

Loading...
Press releases
1 Jul 2025

Thailand’s Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment  

Press releases
13 Jun 2025

Serum Institute of India signs a memorandum of understanding (MoU) with DNDi to advance the development of a new treatment for dengue in low- and middle-income countries

Press releases
13 Jun 2025

K-MEDI and DNDi have initiated collaborative R&D to develop a treatment for neglected diseases

News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License